Literature DB >> 11305353

Monitoring synthetic drug markets, trends, and public health.

I P Spruit1.   

Abstract

The Drugs Information and Monitoring System (DIMS) in The Netherlands is a toxicoepidemiologic monitor of drug markets that was established in 1992. Its main focuses are to identify the compounds of synthetic drugs, describe prevalence and trends, and identify health risks. Here we discuss the insights gained in the Ecstasy market, based on the weekly testing of more than 100 drug samples, and key information of synthetic drug users delivering drug samples and personnel participating in the DIMS network. Pills used as Ecstasy may contain a wide variety of compounds. The percentage of samples containing MDMA increased slowly reaching almost 75% in 1996, but decreasing sharply in 1997. Amphetamines ("speed" and "ice") and experimental varieties were found in at least one third of the pills. Origins and effects of this development are discussed, as well as the risk assessment. In 1998 the percentage of MDMA pills increased more than ever before, indicating among other things that consumers prefer the conventional product. However, the use of "speed" and other drugs may also be stimulated by the decrease in 1997 of the percentage of MDMA pills. With more new types of drugs likely in the next century, a monitor such as DIMS provides important surveillance and data for public health and preventive aims.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305353     DOI: 10.1081/ja-100000227

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  10 in total

1.  New method to monitor drugs at dance venues. Perhaps results of testing tablets should be made public.

Authors:  Jon Cole
Journal:  BMJ       Date:  2002-02-02

2.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

3.  Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

4.  Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.

Authors:  Susan Schenk; David Gittings; Malcolm Johnstone; Evangeline Daniela
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

5.  Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Katherine M Keyes; Silvia S Martins; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2008-06-03       Impact factor: 4.492

6.  Drug checking services for people who use drugs: a systematic review.

Authors:  Nazlee Maghsoudi; Justine Tanguay; Kristy Scarfone; Indhu Rammohan; Carolyn Ziegler; Dan Werb; Ayden I Scheim
Journal:  Addiction       Date:  2021-12-12       Impact factor: 7.256

7.  It's time for Canadian community early warning systems for illicit drug overdoses.

Authors:  Sarah J Fielden; David C Marsh
Journal:  Harm Reduct J       Date:  2007-03-28

8.  'Worth the test?' Pragmatism, pill testing and drug policy in Australia.

Authors:  Andrew Groves
Journal:  Harm Reduct J       Date:  2018-04-10

9.  Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.

Authors:  Sascha B Thal; Miriam J J Lommen
Journal:  J Contemp Psychother       Date:  2018-01-06

10.  Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale.

Authors:  N Maghsoudi; K McDonald; C Stefan; D R Beriault; K Mason; L Barnaby; J Altenberg; R D MacDonald; J Caldwell; R Nisenbaum; P Leece; T M Watson; K W Tupper; L Kufner; A I Scheim; D Werb
Journal:  Harm Reduct J       Date:  2020-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.